Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Intraperitoneal ²¹²Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy

NCT01384253 is registered in ClinicalTrials.gov with Orano Med LLC as lead sponsor.

NCT NCT01384253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01384253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Intraperitoneal ²¹²Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy
Lead sponsor
Orano Med LLC
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2011
Completion date
July 31, 2016
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, ovarian neoplasms, pancreatic neoplasms, peritoneal neoplasms, stomach neoplasms